NEW HIGHLIGHT
Tabrecta

Tabrecta

capmatinib

Manufacturer:

Novartis

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Capmatinib
Indications/Uses
Adults w/ metastatic NSCLC w/ a MET exon 14 skipping mutation.
Dosage/Direction for Use
Administration
May be taken with or without food: Swallow whole, do not break/crush/chew.
Contraindications
Special Precautions
Discontinue use in patients w/ suspected ILD/pneumonitis. Monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (eg, dyspnea, cough, fever). Risk of photosensitivity reactions. Monitor liver function tests (eg, ALT, AST & total bilirubin) prior to start of treatment, every 2 wk during 1st 3 mth of treatment, then once a mth or as clinically indicated, w/ more frequent testing in patients who develop increased transaminases or bilirubin. Use of sunscreen or protective clothing; limit direct UV exposure during treatment. May affect ability to drive & use machines. Severe renal impairment. Men w/ women partners & women of reproductive potential should use effective contraception during treatment & for 1 wk after last dose. Pregnancy. Not to breastfeed during treatment & for 1 wk after last dose. Childn. Elderly.
Adverse Reactions
Peripheral edema, nausea, fatigue, vomiting, dyspnea, decreased appetite.
Drug Interactions
Increased exposure w/ strong CYP3A inhibitors. Decreased exposure & anti-tumor activity w/ strong & moderate CYP3A inducers. Increased exposure of CYP1A2, P-gp & BCRP substrates. Increased exposure of MATE1 & MATE2K substrates.
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01EX17 - capmatinib ; Belongs to the class of other protein kinase inhibitors. Used in the treatment of cancer.
Presentation/Packing
Form
Tabrecta FC tab 150 mg
Packing/Price
60's
Form
Tabrecta FC tab 200 mg
Packing/Price
60's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in